-

11:56:17 PM

CMMB Stock News

CMMB - Chemomab Therapeutics Ltd

09/28/23 7:00 AM

Nasdaq : CMMB

conferenceslow float

Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference

Chemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet...

RHEA-AI

positive

08/14/23 8:00 AM

Nasdaq : CMMB

earningslow float

Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today...

RHEA-AI

neutral

06/28/23 7:00 AM

Nasdaq : CMMB

low float

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high...

RHEA-AI

neutral

06/26/23 7:00 AM

Nasdaq : CMMB

low float

Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023

Chemomab Therapeutics Ltd.,, a...

RHEA-AI

neutral

06/21/23 7:00 AM

Nasdaq : CMMB

clinical triallow float

Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023

Chemomab Therapeutics Ltd.,, a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported...

RHEA-AI

positive

06/05/23 7:00 AM

Nasdaq : CMMB

managementlow float

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

RHEA-AI

positive

06/02/23 9:00 AM

Nasdaq : CMMB

low float

Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis

Chemomab Therapeutics Ltd., a clinical stage biotechnology company...

RHEA-AI

neutral

05/24/23 7:00 AM

Nasdaq : CMMB

conferenceslow float

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

EASL Congress 2023– Vienna, Austria, June 21-24, 2023. EASL Congress 2023– Vienna, Austria, June 21-24, 2023. EASL Congress 2023– Vienna, Austria, June 21-24, 2023.

RHEA-AI

neutral

05/11/23 6:00 AM

Nasdaq : CMMB

earningslow float

Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update

Chemomab Therapeutics, Ltd.,, a...

RHEA-AI

neutral

04/26/23 7:00 AM

Nasdaq : CMMB

conferenceslow float

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company

RHEA-AI

neutral

1 2 3 4 5 6 Next

CMMB Data

IndustryPharmaceutical Preparation Manufacturing
Websitechemomab.com
Security nameChemomab Therapeutics Ltd - ADR
SectorManufacturing

About Chemomab Therapeutics Ltd

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).